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A B S T R A C T
Since 2007, low and middle-income countries (LMICs) have gained experience delivering HPV vaccines through
HPV vaccination pilots, demonstration projects and national programmes. This commentary summarises
lessons from HPV vaccination experiences in 45 LMICs and what works for HPV vaccination introduction.
Methods included a systematic literature review, unpublished document review, and key informant interviews.
Data were extracted from 61 peer-reviewed articles, 11 conference abstracts, 188 technical reports, and 56
interviews, with quantitative data analysed descriptively and qualitative data analysed thematically. Key lessons
are described under ﬁve themes of preparation, communications, delivery, coverage achievements, and
sustainability. Lessons learnt were generally consistent across countries and projects and suﬃcient lessons
have been learnt for countries to deliver HPV vaccine through phased national rollout rather than
demonstration projects. However, challenges remain in securing the political will and ﬁnancial resources
necessary to implement successful national programmes.
1. Introduction
Cervical cancer, caused by human papillomavirus (HPV), is a
leading cause of morbidity and mortality among women in low and
middle-income countries (LMICs), with approximately half a million
new cases and 266,000 deaths annually [1]. Screening programmes,
which have helped reduce mortality rates in high-income countries, are
more challenging to establish in low-resource settings [2,3]. HPV
vaccination has emerged as a cost-eﬀective means of preventing over
70% of cervical cancer cases in all resource settings, and the World
Health Organization recommends HPV vaccination for girls 9–13 years
old [4,5].
Since 2007, many LMICs have gained experience delivering HPV
vaccines through HPV vaccination pilots, demonstration projects and
national programmes. Valuable implementation lessons learnt include
how to achieve community acceptance, obtain parental consent, and
reach adolescent girls for vaccination. Lessons learnt from these
country experiences can inform global and national decision-makers
how best to implement HPV vaccination, whether through phased
introduction or simultaneous national rollout. This commentary sum-
marises major lessons from HPV vaccination experiences in 45 LMICs,
which highlight factors that appear crucial for successful HPV vaccina-
tion introduction [6–8].
2. Methods
The study involved a systematic literature review, unpublished
document review, and key informant interviews [6]. We identiﬁed
LMICs that had completed at least six months of HPV vaccine delivery
through pilot/demonstration projects or national introduction by 30
April 2016. Five peer-reviewed article databases (Medline, Embase,
Global Health, Africa-wide Information, ADOLEC) and two unpub-
lished document databases (Open Grey, ProQuest) were searched
systematically. Websites of national Ministries of Health, WHO
Global Immunisation News, Pan-American Health Organization news-
letters, and HPV scientiﬁc conference abstracts were searched purpo-
sively for unpublished literature and interviewees were asked for
national and sub-national technical reports. We conducted semi-
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MARK
structured key informant interviews with purposively sampled techni-
cal representatives identiﬁed through partners and document searches
(e.g. national immunisation programme managers and HPV coordina-
tors).
We extracted document and transcript data to a standardised
matrix developed for new vaccine introduction [6,8]. Topics included
national decision-making and planning, service delivery, health work-
force, monitoring and evaluation, ﬁnancial support, sustainability, and
scale-up. Qualitative data were analysed thematically, using deductive
and inductive coding. Quantitative data (e.g. coverage, adverse events)
were analysed descriptively to obtain frequencies, proportions, and
scores. The London School of Hygiene & Tropical Medicine Research
Ethics Committee provided study approval.
3. Results
We gathered data from 61 peer-reviewed articles, 11 conference
abstracts, 188 technical reports, and 56 key informant interviews ( >
90% response rate). Forty-six countries were included, as we added one
high-income country (Chile) with a novel, one-dose annually, delivery
system. Countries provided information from 66 demonstration pro-
jects or pilots and 12 national introductions, i.e. 92 distinct HPV
delivery experiences (Fig. 1). We present key ﬁndings below under ﬁve
themes of preparation, communications, delivery, coverage achieve-
ments, and sustainability (Table 1). Further detailed outputs are
available at http://www.rho.org/HPVlessons/ [6–8].
3.1. Preparation
Three key preparation lessons emerged. First, high-level political
commitment contributed to project and national programme eﬀective-
ness, e.g. by increasing HPV vaccine prioritisation and interest,
galvanising collaboration between partners, and strengthening com-
mitments to ﬁnancing and delivery. Second, early inter-ministerial
collaboration was crucial. Collaboration between health and education
ministries enabled cooperation between teaching and healthcare staﬀ.
Engaging private schools early in the planning process encouraged
their participation. Collaboration between health and ﬁnance minis-
tries helped ensure timely funds release. Third, the new target
population and delivery strategies required substantial microplanning
and development of new collaborations between institutions that may
not have worked together previously. Insuﬃcient microplanning led to
considerable problems, particularly for school-based delivery, which
was often new, and where target population numbers needed enumera-
tion.
3.2. Communication
Five key communication lessons emerged [7]. First, eﬀective
community mobilisation activities required implementation at least
one month prior to vaccination and used multiple channels. Second,
the most eﬀective messages emphasised cancer prevention, vaccine
safety, and national and global endorsement (e.g. HPV vaccination
prevents cervical cancer, is safe, will not harm future fertility, and is
endorsed by the government and the World Health Organization),
while explaining clearly where and when girls could be vaccinated.
Third, face-to-face communication between credible inﬂuencers (e.g.
teachers, health-workers, community leaders), parents, and commu-
nities enhanced support and mitigated rumours. Fourth, rumours and
negative publicity were best addressed quickly and comprehensively,
e.g. using several communication channels (celebrity champions, WHO
and government endorsement). Fifth, successful consent procedures
were consistent with those used for routine immunisation. While opt-
out consent was easier logistically, opt-in consent could generate
misunderstanding and mistrust in communities.
Fig. 1. Map of participating countries by project/programme and donor type (as of May 2016). NB: ‘GAP’ is the Gardasil Access Program.
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3.3. Delivery
During the period analysed, over 1.7 million girls were reached and
1.4 million were fully vaccinated [6]. While many delivery lessons were
similar to those for routine vaccination, aspects of HPV vaccination
were new (e.g. target population, usage of schools). Five key delivery
lessons emerged. First, enumerating the population of potentially
eligible girls before vaccination proved challenging and expensive but
necessary because existing population data were normally unreliable or
inaccurate. Investing in enumeration the ﬁrst year improved prepara-
tion in future years, particularly in terms of vaccine register develop-
ment and stock planning. Time and eﬀort required to enumerate and
then track girls between doses was often underestimated. Second,
diﬀerent delivery strategy mixes (e.g. schools, health facilities, out-
reach) could work in diﬀerent contexts within the same country, as
logistics and school enrolment were not homogeneous across each
country. Third, implementing a two-dose vaccination schedule was
easier and cheaper than a three-dose schedule, as the period analysed
included the initial shift from three-dose to two-dose schedules.
Delivery of all doses within one school year minimised dropout and
improved coverage, while providing a second vaccination opportunity
successfully reached girls and parents who initially refused or were
absent/out-of-school. Fourth, using routine vaccination programme
infrastructure and resources (e.g. transport, cold chain, staﬀ) was
easier and more eﬃcient than separate HPV-speciﬁc transport, storage,
or delivery. Fifth, mobilising community health-workers (CHWs) to
assist in identifying out-of-school girls and those who missed doses
improved coverage. Enumerating and vaccinating out-of-school girls
was particularly diﬃcult, with no adequate strategies identiﬁed other
than CHWs mobilising them to self-present at health facilities.
3.4. Coverage
All 51 (77%) demonstration projects and 9 (75%) national pro-
grammes with complete data achieved more than 50% ﬁnal-dose
coverage, with 50 (83%) achieving 70% or higher coverage. Three key
coverage lessons, related to those for delivery, emerged. First, dropout
rates between doses appeared somewhat lower in countries implement-
ing a two-dose vaccination schedule, though data were insuﬃcient to
conﬁrm this. Coverage levels, rivalling some high-income country
programmes, indicate high vaccine acceptability and possible contribu-
tions of dedicated investment and – for Gavi demonstration projects -
emphasis on achieving high coverage in the ﬁrst years. Coverage thus
requires further monitoring so that if coverage rates drop as HPV
vaccination becomes routine or delivery strategies change, remedial
measures can be organised. Second, school-based delivery strategies
were feasible and attained high coverage, though initial eﬀorts were
necessary to coordinate with the Ministry of Education and school
leadership. Third, grade-based eligibility was logistically easier to
implement than age-based in schools, but resulting data were more
challenging to reconcile with health information systems that were
organised around age-based data. Thus, age-based eligibility was easier
for estimating coverage and uptake rates.
3.5. Sustainability
Estimated recurrent ﬁnancial delivery costs, excluding vaccines,
ranged from US$1.11 to 9.21 per dose and diﬀered by funding source.
Three key ﬁnancial sustainability lessons emerged. First, accurate
costing of both vaccines and delivery were critical for countries to
estimate the ﬁnancial resources needed for programme sustainability.
Second, strategies that worked well in demonstration projects were not
always feasible for national scale-up, e.g. due to costs or lack of staﬀ.
Third, funding uncertainties negatively inﬂuenced country decisions to
scale-up HPV vaccination nationally. High HPV vaccine costs com-
bined with high perceived delivery costs that countries must co-ﬁnance
in future, appeared to discourage many policymakers and budget-
holders from committing to HPV vaccination or to change to lower-cost
untested delivery approaches (e.g. facility-based delivery). Thus, rigor-
ous impact data (e.g. economic, human resources) and ongoing
technical assistance with budget planning and economic analyses can
further support the design of sustainable national HPV vaccination
strategies.
4. Conclusions
Lessons learnt were generally consistent across demonstration
projects and supported by smaller studies [9]. However, small project
size, district selection processes, and the desire to demonstrate high
coverage quickly, made some lessons inapplicable to national rollout.
In future, phased national rollout may provide the beneﬁts of demon-
stration projects with the added advantage of maintaining political
commitment to scale-up. Suﬃcient lessons have been learnt for
countries to deliver HPV vaccine through phased national rollout or
national programmes rather than demonstration projects. Countries
now have empirical evidence on the factors that lead to successful HPV
vaccination, yet challenges remain for some countries in securing the
political will and ﬁnancial resources necessary from governments,
donors, and partners to implement successful national programmes.
This is the next major challenge to ensuring potential HPV vaccine
Table 1
Themes and findings on what works for HPV vaccination.
Preparation Ensure high-level political commitment.
Encourage inter-ministerial collaboration early, particularly for health, education, and finance.
Allow sufficient time for planning and micro-planning.
Communication Allow enough time for social mobilisation.
Use clear messaging, focusing on cancer prevention and how to be vaccinated.
Include face-to-face communication with credible influencers.
Respond quickly and thoroughly to rumours and negative media.
Use consent procedures that are consistent with routine immunisation.
Delivery Ensure availability of accurate population data or time and funds for enumeration.
Multiple delivery strategies could be useful within the same country.
Implement a two-dose rather than a three-dose HPV vaccination schedule if possible.
Use routine delivery approaches.
Use community health-workers to help identify missing and out-of-school girls.
Coverage Implement a two-dose vaccination schedule for higher completion rates.
Use school-based delivery to obtain high coverage.
If using grade-based delivery, consider including age in reporting forms.
Sustainability Ensure sufficient time and resources to calculate accurate costing estimates for national rollout of HPV vaccine and delivery.
Choose a delivery strategy that is feasible for national scale-up.
Advocate for sufficient funding to achieve successful national scale-up.
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beneﬁts in reducing cervical cancer morbidity and mortality are
achieved in countries with the highest burden.
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